International Workshop on HIV & Pediatrics 2022
Related Enduring Materials
Day 2 - Thursday, 28 July 2022
Welcome
The 14th International Workshop on HIV & Pediatrics took place as a hybrid meeting from 27-28 July 2022 at Sofitel Montreal Golden Mile in Montreal, Canada. The workshop was attended by 290 attendees (185 in-person and 105 virtual attendees) from 39 countries.
The International Workshop on HIV & Pediatrics 2023 will take place from 21-22 July 2023 in Brisbane, Australia.
Although we have witnessed a dramatic global scale-up of antiretroviral treatment (ART) as well as efforts to prevent vertical HIV transmission in the last decade, there were 160,000 new pediatric infections in 2018 and an estimated 1.7 million children <15 years of age living with HIV. Children are substantially less likely than adults to be diagnosed, initiate treatment, and achieve durable viral suppression. Currently, only 54% are receiving ART, and treatment of pediatric HIV infection, particularly in infants and young children, remains complex and problematic, with continued use of suboptimal ART formulations and regimens.
Furthermore, adolescents are one of the most rapidly growing populations with HIV; in 2018, there were an estimated 510,000 new HIV infections among young people aged 15- 24 years, accounting for 30% of all new HIV infections globally. HIV infections among adolescent girls and young women are 60% higher than among adolescent boys and young men of the same age, with 6,000 new infections occurring in young women weekly. HIV remains one of the leading causes of death among adolescents living in Africa and among the top 10 causes of death in adolescents globally. The uptake of HIV testing among adolescents has remained low. Programs continue to struggle to reach and retain adolescents in care, and adherence to treatment has special challenges, particularly among those with perinatal infection aging up into adolescence and young adulthood.
As research to improve pediatric HIV diagnosis and care is ongoing, new scientific questions of critical importance have also emerged. In settings with mature ART programs, an increasing proportion of new pediatric infections is attributed to women acquiring HIV infection during pregnancy and breastfeeding, periods of markedly increased risk of HIV acquisition for the mother. With the scale-up of ART for PMTCT, the prevalence of pre-treatment antiretroviral (ARV) drug resistance, particularly to non-nucleoside reverse transcriptase inhibitor drugs, has escalated among newly diagnosed infants, jeopardizing ART effectiveness. Additionally, with more than 1.3 million pregnant women globally receiving ART, there are increasing concerns about the long-term impact of in utero and postnatal exposures to medications for those children who escape HIV.
Currently, the global population of HIV-exposed uninfected children and adolescents is estimated at 14.8 million, including over 8 million with in utero ARV exposure. Recent findings of an association with periconception dolutegravir exposure and increased risk of neural tube defects have underscored the need for ongoing attention to the safety of ARVs in pregnancy. Innovation in early infant diagnosis such as point of- care tests has facilitated earlier identification of HIV infection during infancy, providing exciting new opportunities to study acute infection and very early treatment in neonates and promising remission strategies. However, despite the critical importance of these topics, research in pediatric, adolescent, and maternal HIV infection is often neglected at major scientific HIV conferences.
Therefore, in collaboration with leading experts in the field, we have established a highly focused international workshop on the prevention and treatment of pediatric HIV infection. The overall objective of the International Workshop on HIV Pediatrics is to stimulate research that will advance prevention and treatment strategies for infants, children, and adolescents.
Local Co-Chairs 2022
Workshop Chairs
General Information
Address:
1155 Sherbrooke Street West
Montreal, Quebec H3A 2N3
Canada
- A good representation of organizations involved in HIV treatment and care in HIV & Pediatrics.
- Special Session to address the most recent research.
- Early-career investigator awards for best oral presentation and best poster presentation.
- 6 dedicated poster walks.
- 28 (mini-) oral presentations.
- An extraordinary record of supporting scientific achievement as demonstrated in the success across the cascade from abstract presentation to publication.
- Clinicians
- Nurses
- Industry specialists working in academic settings, hospitals, and non-governmental organizations (NGO)
- Enhancing communication and encouraging new collaborations between junior and senior investigators, north and south, and academia, governmental public health agencies, and industry to promote advances in HIV prevention and care in children, youth, and families.
- Disseminating knowledge and data exchanged by workshop participants beyond the audience of the live event through the posting of all presentations on the meeting website, thus maximizing the impact of the meeting by reaching the whole HIV research community.
- Providing updates on the latest research on new pediatric antiretroviral drugs and treatment and prevention strategies in children and adolescents.
- Evaluating the effectiveness of and gaps in programs for the prevention of perinatal HIV transmission and interventions to improve such programs.
- Sharing results from implementation science research on how to optimally implement proven interventions for the prevention of perinatal HIV transmission and pediatric and adolescent care and treatment in developing countries.
- Understanding complications of long-term HIV and its therapy, to enable improved management of HIV in children and adolescents.
- Describe the changing epidemiology of the pediatric HIV epidemic worldwide and the latest recommendations for pediatric and adolescent HIV treatment.
- Describe the impact of the COVID-19 pandemic on pediatric and maternal HIV programs and what we know about SARS-CoV-2 infection in African children.
- Summarize optimal treatment and management strategies of HIV infection in infants, children, adolescents, and pregnant and postpartum women.
- Describe potential complications of HIV and newer HIV treatments on children, adolescents, and pregnant/postpartum women.
- Summarize strategies to improve perinatal HIV prevention programs and to better understand the continued risk for perinatal transmission in the ART era.
- Describe special issues related to HIV in adolescents and young people and new HIV prevention modalities and programming options for youth.
- Understand new long-acting prevention technologies and their application for the prevention of HIV in adolescents.
Practical Information
You are allowed to travel to Canada if:
- You qualify as fully vaccinated; *
- You have received at least two COVID-19 vaccine doses and the second was at least 14 days before your planned arrival to Canada (or one dose of the Janssen/Johnson & Johnson vaccine);
- You have no signs or symptoms of COVID-19;
- Your proof of vaccination is in English/French or you have a certified translation in English/French;
- You have your ArriveCAN receipts including your vaccination, contact and travel information;
*Accepted Vaccines are considered the following:
- AstraZeneca/COVISHIELD (ChAdOx1-S, Vaxzevria, AZD1222)
- Bharat Biotech (Covaxin, BBV152 A, B, C)
- Janssen/Johnson & Johnson – 1 dose
- Medicago Covifenz
- Moderna (Spikevax, mRNA-1273) including for children aged 6 to 11 years
- Novavax (NVX-COV2373, Nuvaxovid, Covovax)
- Pfizer-BioNTech (Comirnaty, tozinameran, BNT162b2) including for children aged 5 to 11 years
- Sinopharm BIBP (BBIBP-CorV)
- Sinovac (CoronaVac, PiCoVacc)
For more information, visit our COVID-19 tab.
To apply for a visitor VISA you will need to upload online the below documents:
- Proof of vaccination
- ArriveCAN receipt (electronic or paper)
- Identity document
To apply for an eTA you will need to complete an online form and submit the below documents:
- A valid passport from a visa-exempt country
- A valid email address
You can find more information here: https://www.cic.gc.ca/english/visit/visas.asp
Translation will not be provided.
Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Registration is closed.
Fees and Conditions
|
Academia - Physical Participation |
Academia -Virtual Participation |
Industry - Physical/Virtual Participation |
|
|---|---|---|---|
|
Early Fee (payment before/on 26 January 2022) |
€395.00 |
€197.50 |
€1395.00 |
|
Regular Fee (payment before/on 26 May 2022) |
€595.00 |
€297.50 |
€1695.00 |
|
Late Fee (payment before/on 26 July 2022) |
€795.00 |
€397.50 |
€1795.00 |
|
Same Day Fee (payment from 27 to 28 July 2022) |
€895.00 |
€447.50 |
€1895.00 |
|
Discounts |
|
|---|---|
|
Early-Career Investigators / Academia from Resource-Limited Settings (RLS)* WITH an accepted abstract |
Fee Waived |
|
Early-Career Investigators / Academia from Resource-Limited Settings (RLS)* WITHOUT an accepted abstract |
50% Off Current Academia Fee |
|
Academia from high-income countries WITH ACCEPTED ABSTRACT |
Early Academia fee |
|
NGO Representatives / Government Representatives (i.e. MOH, NIH, NIAID, etc.) / Advocates |
50% Off Current Academia Fee |
|
Members of Endorsers |
25% Off Current Academia Fee |
|
Sponsors |
Contact Secretariat |
If eligible for a discount, please contact the workshop secretariat via christina.moustakaki@amededu.com for the special registration code.
*Countries included in the low-income and middle-income economies list of the World Bank Classification
**If you have financial concerns, please contact the workshop secretariat.
Important
-
We strongly advise that you register early to ensure that your registration is secured.
-
Submission of your online registration does not guarantee that your registration has been accepted. Your registration is final when full prepayment has been received and a confirmation of your registration has been sent.
- Virtual Workshop pack, including abstract book and program
IMPORTANT:
- Payment can only be made by credit card.
- Virology Education reserves the right to cancel improper registrations. Claims for a refund will not be honored.
IMPORTANT: The registration fee is waived for the presenting author only.
To be eligible as an early-career investigator, one should either be a current Master/PhD student or have obtained an MD/PharmD/PhD degree in the last five years. An application form needs to be completed by a supervisor and received by the Virology Education secretariat at least two weeks prior to the start of the workshop. Virology Education will contact the early-career investigator with instructions regarding the registration procedure.
- Cancellation before/on 16 June 2022: 50% refund (minus an administration fee of €40)
- Cancellation after 16 June 2022: Unfortunately, no refund will be given
If you are unable to attend the workshop, a substitute delegate is always welcome at no extra charge, provided that a letter of authorization from the original participant has been received and the conference secretariat has been notified of the name of the substitute delegate before 20 June 2022. A statement (email/letter) of cancellation must be sent to Virology Education.
1. Proof of accreditation
2. Valid identification (e.g. passport)
3. A letter from your assignment giver stating the details of your assignment (e.g. editor)
4. At least 3 previously written assignments in recognized outlets on HIV. If you are a freelance journalist, the assignments can be from different (recognizable) news outlets. Links to online publications are accepted
5. The website of the publication(s)/blog(s) that will be featuring your story on this workshop
A free or reduced registration fee may apply for accredited media participants depending on availability. Preference will be given to credible print and online news sources. Please contact the workshop secretariat for registration conditions.
We would like to receive a copy of your workshop report/ article once it is finalized.
All credentials will be verified by the Organizing Committee of the Workshop. Media representatives are kindly requested to register by sending the above-mentioned information to info@amededu.com.
Important: Media is restricted to the written press. Recording on film or photo is not allowed. Virology Education will request a copy of the written piece once it is finalized. Media representatives must also agree to abide by the 2021 embargo policy.
The Abstract Submission Portal is now closed.
Abstracts can be submitted under the following categories:
- HIV (and STI) Prevention in Adolescents
- HIV Prevention in Pregnant and Breastfeeding Persons
- Prevention of Vertical HIV Transmission – Interventions and Implementation
- Clinical Issues in HIV-Exposed Uninfected Children
- Pediatric HIV Case Finding Including Early Infant Diagnosis
- Antiretroviral HIV Treatment in Infants, Children, and Adolescents (Including ARV Switch, Toxicity, Drug Resistance)
- Antiretroviral Treatment Issues in Pregnant and Breastfeeding Persons (Including ARV Switch, Toxicity, Effects on Pregnancy Outcome)
- Clinical Management Issues for Infants, Children, and Pregnant/Breastfeeding Persons (e.g., Monitoring, Differentiated Care)
- Clinical Management Issues Specific to Adolescents (e.g. Transition to Adult Care)
- Coinfections/Complications of HIV/Treatment in Infants, Children, Adolescents, and Pregnant/Breastfeeding Persons
- COVID-19 in Children/Adolescents/Pregnancy and COVID-19 Impacts on HIV Care
IMPORTANT: The registration fee is waived for the presenting author only.
To be eligible as an early-career investigator, one should either be a current Master/PhD student or have obtained an MD/PharmD/PhD degree in the last five years. An application form needs to be completed by a supervisor and received by the Virology Education secretariat at least two weeks prior to the start of the workshop. Virology Education will contact the early-career investigator with instructions regarding the registration procedure.
- Background: A concise statement of the issue under investigation or a hypothesis;
- Material and Methods: The experimental methods used (including the statistical analyses employed);
- Results: Specific findings (promises such as "to be completed" or "to be presented" are not acceptable);
- Conclusions: A summary of findings that are supported by your results (statistical analyses used to support the conclusions, where appropriate, should be included; concluding statements such as "the results will be discussed" are not acceptable).
Please note that abstracts cannot be accepted if tables or graphs are included. The maximum word count for the abstract body is 350 words.
Abstracts are considered official communications to the workshop and will be treated confidentially. Submitters of accepted abstracts agree to attend the workshop and present their abstract as scheduled.
VE and AME is the sole copyright holder of the workshop abstract book as a whole (also referred to as the Reviews in Antiviral Therapy & Infectious Diseases). The abstract authors will retain any and all copyright over their individual abstract. Information on copyright can be viewed in the abstract submission terms and conditions (see 'Terms and Conditions' above).
- Please prepare your presentation in PowerPoint
- PC’s will be used for the presentations. If you are working on a MAC computer, you need to format your presentation to a PC-compatible file and check the layout of your presentation before handing it in.
- Avoid too many animations, use common fonts (Arial), readable font size (> 16), and clear colors.
- Submit your presentation on an USB stick (please double-check your USB stick for computer viruses).
- We kindly request that you make your way to the front of the room at least 5 minutes before the start of the session.
- The measurements of the poster should not exceed 3ft x 4ft (90 cm x 120 cm) posted in portrait format.
- Please display your abstract number in the upper right corner of your poster.
- Adhesive material for your poster will be provided by the workshop secretariat.
- We would like to ask you to also prepare hand-outs of your poster.
- Your poster should be displayed during both workshop days.
Workshop Chairs 2022
The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop, identify interesting topics and candidate speakers, and review all submitted abstracts.
Scientific Committee
We are proud to present the members of the committee:
-
Ellen Chadwick, MD - Ann & Robert H. Lurie Children’s Hospital of Chicago / Northwestern University Feinberg School of Medicine, United States
-
Tsungai Chipato, MBChB - University of Zimbabwe College of Health Sciences, Zimbabwe
-
Polly Clayden - HIV i-Base, United Kingdom
-
Anita De Rossi, PhD - University of Padova / Istituto Oncologico Veneto (IOV)-IRCCS, Italy
-
Marinella Della Negra, MD, PhD - Hospital Emilio Ribas, Brazil
-
Brian Eley, MD - University of Cape Town, South Africa
-
Albert Faye, PhD - Denis Diderot University, Paris, France
-
Rashida Ferrand, MBBS, FRCP, PhD - London School of Hygiene and Tropical Medicine / Biomedical Research and Training Institute, Zimbabwe
-
Pat Flynn, MD - St. Jude Children's Research Hospital, United States
-
Tessa Goetghebuer, MD - Office de la Naissance et de l'Enfance / CHU Saint-Pierree, Belgium
-
Ali Judd, PhD, MRC Clinical Trials Unit, University College London, United Kingdom
-
Valériane Leroy, MD - Inserm, Paris, France
-
Chewe Luo, MD, PhD - UNICEF, United States
-
Dorothy Mbori-Ngacha, MBChB, MMed, MPH - UNICEF, South Africa
-
Sharon Nachman, MD - SUNY Stony Brook / IMPAACT, United States
-
Paul Palumbo, MD - Dartmouth-Hitchcock Medical Center, United States
-
Martina Penazzato, MD, MSc, PhD - World Health Organization, Switzerland
-
Ann Petru, MD - UCSF Benioff Children's Hospital Oakland, United States
-
Natella Rakhmanina, MD, PhD, FAAP, FCP, AAHIVS - Elizabeth Glaser Pediatrics AIDS Foundation / Children’s National Hospital, United States
-
Theodore Ruel, MD - UCSF Benioff Children's Hospital San Francisco, United States
-
George Siberry, MD, MPH, FAAP, FPIDS - United States Agency for International Development (USAID), United States
-
Lynda Stranix-Chibanda, MBChB, MMed - University of Zimbabwe, Zimbabwe
-
Tavitiya Sudjaritruk, MD, ScM, PhD - Chiang Mai University, Thailand
-
Graham Taylor, MD - Imperial College, United Kingdom
-
Claire Thorne, BA, MSc, PhD - University College London, United Kingdom
-
Marissa Vicari - International AIDS Society, Switzerland
-
Rachel Vreeman, MD, MS - Icahn School of Medicine at Mount Sinai, United States
The members of Scientific Committee are hand-picked by the Organizing Committee and the workshop secretariat based on their significant contributions and commitment to the field. They assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.
The Scholarship Portal is now closed.
Virology Education (VE), with support from the industry, is offering scholarships to attend HIV & Pediatrics 2022.
Depending on the type of scholarship awarded, the scholarship covers registration and/or travel and accommodation.
(The scholarships are supported by industry. These companies will have no control, influence, or involvement in the selection of any attendees.)
What Does the Scholarship Cover?
Registration Scholarship:
- Registration only
Partial Scholarship:
- Registration
- Accommodation
Full Scholarship:
- Registration
- Accommodation
- Travel
What is Expected from the Scholarship Recipients?
All scholarship awardees are required to attend the full workshop. Awardees must sign in at the beginning of each meeting day and sign off at the end of each day as requested by the Workshop Organizer. At the close of the workshop, awardees must have completed the daily and overall workshop evaluations.
The recipient will provide post-meeting feedback and a summary of his/her/their workshop experience within one month after the end of the workshop. The feedback questionnaire will be an online survey with the recipient providing feedback on their experience at the workshop, scholarship procedure, and how they will implement the knowledge acquired at the meeting in their daily practice. The questionnaire will be sent to each recipient by email within one week after the conclusion of the workshop.
Eligibility
Applicants must:
- Be proficient in English to interact with faculty and fellow attendees
- Be actively involved in the field of HIV & Pediatrics
- Be able to show benefits to their patients / research / community from attending the workshop
- Be willing and able to share information learned at the workshop with a larger community
- Workshop organizer will automatically decline all scholarship applications that do not conform to the eligibility terms
Application Procedure
The scholarship applications must be submitted online through our Scholarship Application Portal by 29 April 2022. The applicant will be asked to submit a motivational letter (max. 200 words) describing how their patients / research / community will benefit from the knowledge gained at this meeting, and their knowledge dissemination strategy, a CV, and a letter of recommendation (optional).
- All applications will be acknowledged upon receipt.
- All applications will be reviewed by an independent Scholarship Review Committee.
- All applicants will be notified about the status of their application in mid-May 2022.
- Successful applicants will be sent a scholarship agreement.
- After receipt of the signed scholarship agreement, successful applicants will receive instructions for logistical arrangements.
Selection Criteria
The following criteria will be taken into consideration during the selection process:
- Professional background
- Supervisor recommendation
- Demonstrated benefits to patients / research / community by the knowledge to be gained at this meeting
- Strategy of knowledge dissemination
- Early-Career Investigator status
- Country of residence
Important
- Incomplete applications will not be considered. Workshop Organizer cannot be held responsible for any incorrect information that is submitted through the scholarship application portal.
- Retrospective applications will not be considered.
- Scholarship recipients must attend the entire workshop.
- Scholarships are non-transferrable.
- Workshop Organizer cannot guarantee awarding the scholarship to prospective scholarship recipients until the confirmation of available funds. In the event that sufficient funding for the scholarship is not available, Workshop Organizer will not be liable for any expenses or damages incurred by the prospective scholarship recipient with regards to the scholarship application and/or preparation for the meeting.
- Applications will be considered until the exhaustion of funds.
- Scholarship recipients will be responsible for all other costs associated with workshop attendance.
- Workshop Organizer will not be liable for any injury, death, damage, loss, delay, cost, expense, or inconvenience, causes of action claims and suits for property damage, theft of property or personal injury (including death) arising in connection with the scholarship and participation in the Workshop .
- Workshop Organizer reserves the right to make the final decision regarding all applications, which cannot be disputed.
Support Our Initiative
Financial backing helps us deliver an impactful meeting experience for the benefit of healthcare professionals and community representatives involved in HIV and pediatrics.
This collaboration plays a vital role in both the organizational as well as scientific success of the program.
To show your commitment to the cause and get in touch with us for a tailored support package, please contact Ms. Karin Siebelt at Karin@amededu.com or call +31 30 2307146.
Benefits of Support
By supporting this program, we can offer the following advantages for your company.* Please contact us for the most recent support level benefits for this program.
• Symposium opportunities
• Verbal acknowledgment during the program
• Discounted and complimentary registrations for your representatives
• Company acknowledgment on digital meeting materials including but not limited to newsletters, flyers, program book, the streaming platform, and our website
• Digital and printed advertising opportunities
• Social media shout-outs
• Logo on the digital conference bag
*Subject to the support level
Endorsers
HIV & Pediatrics 2022 is endorsed by societies and organizations. Their support and collaboration are key to the success of this workshop!
If you would like your organization to endorse this workshop, please contact Christina Moustakaki at Christina.Moustakaki@amededu.com.
Group Photo
Invitation to Join the International Workshop on HIV & Pediatrics | 27-28 July 2022
Fatima Kakkar, MD, MPH, FRCPC
CHU Sainte-Justine / Université de Montréal, Canada
Jason Brophy, MD, MSc, DTM, FRCPC
Children's Hospital of Eastern Ontario, Canada
Previous Editions
- 13th Edition - International Workshop on HIV Pediatrics, 2021, Virtual
- 12th Edition - International Workshop on HIV Pediatrics, 2020, Virtual
- 11th Edition - International Workshop on HIV Pediatrics, 2019, United States
- 10th Edition - International Workshop on HIV Pediatrics, 2018, The Netherlands
- 9th Edition - International Workshop on HIV Pediatrics, 2017, France
- 8th Edition - International Workshop on HIV Pediatrics, 2016, South Africa
- 7th Edition - International Workshop on HIV Pediatrics, 2015, Canada
Top-Rated Materials from Previous Editions
Pediatric HIV Treatment and Prevention: What's New for 2021 - Martina Penazzato, MD, MSc, PhD
International Workshop on HIV Pediatrics 2021
Health & Safety Measures regarding COVID-19
Ensuring the health and safety of our attendees, suppliers, and staff is our absolute number one priority. In order to provide a safe conference environment, all hybrid and live events organized by Virology Education will follow the national health and safety measures of the country where the meeting is being held in. We kindly ask that all attendees carefully abide by these measures to assist us in ensuring a safe environment for all.
National Health & Safety Measures
The health and safety measures that will be taken by Virology Education during the International Workshop on HIV & Pediatrics are listed on the government website of Canada. Please read them very carefully before travelling to the conference venue.
Our staff will be available onsite to address any questions or concerns that you might have. If you have any questions in advance, please contact the Conference Secretariat at christina.moustakaki@amededu.com.
Travelling to Canada
Virology Education strongly advises participants to check the government website of Canada for the latest and most accurate information about the rules regarding travel.
Please be aware of measures such as testing requirements, vaccination requirements, whether your country of origin is mentioned on the Red List, etc.
What if I get ill during the event?
Should an attendee become ill or exhibit COVID-19 symptoms at any time during the event, the attendee will safely withdraw from the event venue and immediately notify the event organizer with details of other attendees which have been in close contact at the event. By registering for the event, the attendee declares, acknowledges, and accepts that they will comply with all local government requirements should they become ill or exhibit COVID-19 symptoms during the event.
Liability Waiver
Virology Education cannot guarantee that its participants, volunteers, partners, or others in attendance will not become infected with COVID-19.
To the maximum extent permitted by law, Virology Education accepts no liability for any illness, COVID-19 related or otherwise, that may subsequently be contracted after or during the event.
All participants acknowledge and agree that they are attending the event at their own risk.
